Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1186/s12933-020-01090-9 http://scihub22266oqcxt.onion/10.1186/s12933-020-01090-9 32698837!7375203!32698837     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cardiovasc+Diabetol 2020 ; 19 (1): 115 Nephropedia Template TP {{tp|p=32698837|t=2020. Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies |pdf=|usr=}}{{32698837}} gab.com Text Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies JO: Cardiovasc Diabetol http://www.kidney.de/pget.php?&tw=1&pmid=32698837 #FOAvip The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection in order to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients. Twit Text FOAVip Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies ????Cardiovasc Diabetol http://www.kidney.de/pget.php?&tw=1&pmid=32698837 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32698837 #FOAvip English Wikipedia <ref>{{Cite pmid|32698837}}</ref> Treating type 2 diabetes in COVID-19 patients: the potential benefits of injective therapies #MMPMID32698837 Longo M; Caruso P; Maiorino MI; Bellastella G; Giugliano D; Esposito K Cardiovasc Diabetol 2020[Jul]; 19 (1): 115 PMID32698837show ga The coronavirus disease 2019 (COVID-19) has been declared as pandemic by the World Health Organization and is causing substantial morbidity and mortality all over the world. Type 2 diabetes, hypertension, and cardiovascular disease significantly increase the risk for hospitalization and death in COVID-19 patients. Hypoglycemia and hyperglycemia are both predictors for adverse outcomes in hospitalized patients. An optimized glycemic control should be pursued in patients with diabetes and SARS-CoV-2 infection in order to reduce the risk of severe COVID-19 course. Both insulin and GLP-1RAs have shown optimal glucose-lowering and anti-inflammatory effects in type 2 diabetic patients and may represent a valid therapeutic option to treat asymptomatic and non-critically ill COVID-19 diabetic patients. |Betacoronavirus/*pathogenicity[MESH] |Biomarkers/blood[MESH] |Blood Glucose/*drug effects/metabolism[MESH] |COVID-19[MESH] |Clinical Decision-Making[MESH] |Coronavirus Infections/diagnosis/epidemiology/*therapy/virology[MESH] |Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy/epidemiology[MESH] |Glucagon-Like Peptide-1 Receptor/agonists[MESH] |Host Microbial Interactions[MESH] |Humans[MESH] |Hypoglycemic Agents/*administration & dosage/adverse effects[MESH] |Incretins/*administration & dosage/adverse effects[MESH] |Insulin/*administration & dosage/adverse effects[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/epidemiology/*therapy/virology[MESH] |Risk Assessment[MESH] |Risk Factors[MESH] |SARS-CoV-2[MESH]Treating type 2 diabetes in COVID-19 patients: the potential benefits (epmc).pdf DeepDyve Pubget Overpricing